The short version
Retatrutide acts at three hormone receptors: GIP, GLP-1 and glucagon. The selected studies below cover different populations and trial phases, so their percentages are not directly interchangeable.
An investigational profile is not an endorsement or a finding of safety.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Retatrutide
- Research name · The compound name used in the research literature.
- LY3437943
- Research identifier · Development identifier used in trials.
- Reta
- Informal shorthand · A shortened name used in discussion.
- GLP-3 / GLP3 / GLP-3 RT
- Informal seller label · Used to refer to retatrutide in some listings. It is not the formal research name and does not verify what a product contains.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Which trial population is behind a weight-loss percentage?
The selected phase 3 trial enrolled people with type 2 diabetes. Its results should not be treated as interchangeable with a trial in a different population, or as a personal forecast.
Study-specific context · TRIUMPH-2 original study ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
Selected randomized human trials include phase 2 obesity research and phase 3 research in people with type 2 diabetes. These summaries do not cover the entire development program.
Selected phase 2 obesity trial (2023)
Summary based on: Published abstract
- Study design
- Randomized, double-blind, placebo-controlled phase 2 trial; 48 weeks.
- Who was studied
- 338 adults with obesity or overweight and a weight-related condition.
- Route and preparation
- Subcutaneous injection of the investigational study drug.
- What was compared
- Several weekly injected retatrutide regimens versus placebo.
- What researchers found
- At 48 weeks, average weight changes ranged from −8.7% to −24.2% across active groups, versus −2.1% with placebo. Gastrointestinal events were most common; dose-related heart-rate increases were also reported.
- What this leaves unanswered
- These are results for specific trial groups, not an individual forecast. They cannot verify commercial products. This selected trial does not cover newer phase 3 findings.
- Funding context
- The publication reports funding from Eli Lilly; funding and conflicts warrant consideration alongside the study design.
TRIUMPH-2 · obesity and type 2 diabetes (2026)
Summary based on: Published abstract
- Study design
- Randomized, double-blind, placebo-controlled phase 3 trial; 80 weeks.
- Who was studied
- 1,152 adults with BMI at least 27 and type 2 diabetes, at 92 sites in eight countries.
- Route and preparation
- Subcutaneous injection of the investigational study drug.
- What was compared
- Weekly injected retatrutide in 4, 9 or 12 mg study groups versus placebo.
- What researchers found
- Mean weight changes were −11.9%, −16.8% and −18.8% in those groups, versus −5.1% with placebo, using the treatment-regimen analysis, which included estimates for missing data.
- Adverse events and stopping treatment
- Gastrointestinal events, low blood pressure and altered skin sensation were more common with retatrutide. Treatment discontinuation for adverse events or death was 4%, 12% and 8%, versus 5% with placebo; investigators judged reported deaths unrelated to treatment.
- What this leaves unanswered
- These group averages concern people with type 2 diabetes, not every person seeking weight loss. Missing data required statistical assumptions. An 80-week trial cannot establish lifelong safety or verify a commercial preparation.
- Funding context
- Eli Lilly funded the trial; several authors were company employees and shareholders.
Research terms in everyday language ↗
Selected abstract-based summaries now include TRIUMPH-2 (2026). Full-text appraisal, other phase 3 trials, and complete safety and conflict reviews remain pending.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- GIP + GLP-1 + glucagon receptor agonist
- Name variations
- Names you may see and important distinctions
- Source type
- Regulatory safety notice
- Reference jurisdiction
- United States
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 7 November 2026 · Opens in a new tab
Identifies continuing development; a developer statement is not independent clinical appraisal.
For athletes: competition rules are a separate check ↗